Teucrium Corn Fund vs Summit Therapeutics Inc — how do they compare? Teucrium Corn Fund trades at $18.99 (market cap $125.39M), while Summit Therapeutics Inc trades at $17.6 (market cap $13.71B). The key difference: Summit Therapeutics Inc is far larger — about 109.3× Teucrium Corn Fund's market cap, and Teucrium Corn Fund is trading nearer its 52-week high, Summit Therapeutics Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Teucrium Corn Fund for 26 Days and Summit Therapeutics Inc for 16 Days on average.
| CORN | SMMT | |
|---|---|---|
Market Cap | $125.39M | $13.71B |
Volume | 271,634 | 6,173,057 |
Sector | Commodities - Metals/Agriculture | Health |
52-Week High | $20.29 | $26.38 |
52-Week Low | $16.46 | $12.43 |
Typical Hold Time | 26 Days | 16 Days |
Enterprise Value | — | $13.04B |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Summit Therapeutics (SMMT) trades at $17.95, up 3.7% with strong technical momentum and bullish analyst sentiment. The stock shows negative profitability metrics but benefits from AstraZeneca's $2 billion strategic investment and clinical collaborations. Recent news highlights positive clinical trial results for ivonescimab, driving investor optimism despite current financial losses.
The outlook remains speculative with significant upside potential based on analyst consensus targets averaging $29.33, though high valuation multiples and negative cash flows present substantial risk. Success of clinical trials and partnership execution will determine long-term value creation for shareholders.
Trailing returns across standard periods
Latest headlines on both assets
CORN is a commodity ETF that provides exposure to the price of corn futures. It uses a laddered investment strategy across multiple benchmark contracts to help minimize the impact of contango and roll costs in the agricultural market.
Read more on CORN →Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →